Alteration in progression of murine autoimmune disease by treatment with a novel immunomodulator, SM-8849.
The effects of SM-8849 on the development of autoimmune disease in MRL/Mp-1pr/1pr mice were examined. SM-8849 improved survival as well as renal disease, restored the deficits in splenic cell responsiveness to stimulation by mitogens or conventional antigens, and prevented lymphadenopathy and splenomegaly coincident with a decrease in the number of Thy-1+/Lyt-2-/L3T4- cells. SM-8849 also suppressed the production of the B-cell differentiation factor, possibly with a resulting preferential reduction of autoantibodies. In addition, SM-8849 depressed the production of hydrogen peroxide from macrophages. These results suggest that the administration of SM-8849 to a subject with autoimmune diseases can induce immunological improvements with possible clinical effectiveness.
Nishikaku
F
F
Research Laboratories, Sumitomo Pharmaceuticals Co., Ltd, Osaka, Japan.
Koga
Y
Y
D000818:Animals; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D005921:Glomerulonephritis / Q000188:drug therapy; D006861:Hydrogen Peroxide / Q000378:metabolism; D006942:Hypergammaglobulinemia / Q000188:drug therapy; D066298:In Vitro Techniques; D015850:Interleukin-6 / Q000378:metabolism; D008206:Lymphatic Diseases / Q000188:drug therapy; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D013154:Spleen / Q000276:immunology; D013163:Splenomegaly / Q000188:drug therapy; D013601:T-Lymphocytes / Q000276:immunology; D013844:Thiazoles / Q000627:therapeutic use*
D001323:Autoantibodies; D001713:Biphenyl Compounds; D015850:Interleukin-6; D013844:Thiazoles; C072865:4-(1-(2-fluoro-4-biphenyl)ethyl)-2-methylaminothiazole; D006861:Hydrogen Peroxide